Shire Supports Rare Disease Day 2010
By Shire Pharmaceutical, PRNESunday, February 28, 2010
CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced it will actively support Rare
Disease Day across the world by generating media coverage in many countries
to raise awareness and understanding of rare diseases.
Rare Disease Day seeks to call attention to rare diseases as a public
health issue, and to reinforce the increased need for access to information,
research and treatment. It is coordinated at the international level by
European Organisation for Rare Diseases (EURORDIS) and by the National
Organization for Rare Disorders (NORD) in the US.
It is estimated that there are between 5,000 and 8,000 known rare
diseases affecting 250 million people in the world. Shire has commercially
approved and available treatments for Fabry disease, Hereditary Angioedema
(HAE) and Hunter syndrome. In addition, Shire expects the U.S. Food & Drug
Administration (FDA) to issue its decision for VPRIVTM (velaglucerase alfa
for injection), Shire's investigational enzyme replacement treatment for Type
1 Gaucher disease, by February 28.
"For many patients and their families, the journey to a diagnosis and
subsequent treatment can be a long, complicated process," said Sylvie
Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is
committed to enabling people with life-altering conditions to lead better
lives - and for us, this includes improving access to information as well as
providing much-needed treatment for rare diseases."
Shire's Global Rare Disease Day Initiatives include:
- Extending BraveCommunity.com (www.bravecommunity.com), its online resource center that aims to connect patients with each other and to provide important information about rare diseases. - Supporting the Global Genes Project (www.globalgenesproject.org) , a grassroots effort to use denim jeans to raise global awareness of rare genetic disorders. - Supporting its non-profit partners as they visit Capitol Hill to advocate for patients with rare diseases in Washington, D.C., - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the Annual Running Race for Rare Disease Day in Madrid, Spain. - Organizing a special walk on February 28th in Brazil to raise awareness of rare diseases in the country. It is expected that more than 20 patient organizations and their members will participate.
For the full press release please visit www.bravecommunity.com
Media Contact
Jessica Mann (Rest of the World) +44(0)1256-894-280
Jessica Cotrone (North America, HGT) +1-617-613-4640
www.shire.com
Media contact: Jessica Mann (Rest of the World) +44(0)1256-894-280, Jessica Cotrone (North America, HGT) +1-617-613-4640
Tags: Cambridge, England, March 1, Massachusetts And Basingstoke, Shire Pharmaceutical, United Kingdom, United States of America